Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable file. CIT can also broadcast NIH-only or HHS-only content.

NCI Experimental Therapeutics Program - Chemical Biology Consortium

Loading video...

 
   
Air date: Monday, August 10, 2009, 8:30:00 AM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 148 * This only includes stats from October 2011 and forward.
Category: Conferences
Runtime: 06:22:46
Description: The purpose of this meeting is to announce and define the goals, process and procedures for the NCI’s Experimental Therapeutics (NExT) Program and of the newly created Chemical Biology Consortium (CBC). The Division of Cancer Treatment and Diagnosis (DCTD) and the Center for Cancer Research (CCR) are working in close collaboration to reinvigorate cancer drug development at NCI. Through a joint early therapeutics development program, extramural and intramural teams have prioritized a pipeline of NCI-driven targeted therapeutics for development. This program, called the NCI Experimental Therapeutics (NExT) program, combines the strengths of DCTD’s extensive expertise in anticancer drug development with CCR’s dynamic in-house research and its location within state-of-the-art facilities at the NIH Clinical Center. To further augment the discovery efforts of the NCI, DCTD is creating the Chemical Biology Consortium to enable the use and development of ultra-High Throughput Assays related to targets of interest for the purpose of developing hits that can then be optimized through iterative cycles of medicinal chemistry during the progression from in silico to in vitro to in vivo studies to define the anti-tumor activity of these new molecular entities.

List of speakers:
  • Dr. John Niederhuber, Director, NCI
  • Dr. James H. Doroshow, Director, DCTD
  • Dr. Joseph E. Tomaszewski, Deputy Director, DCTD
  • Dr. L. Michelle Bennett, Deputy Director, CCR
  • Dr. Jamie Zweibel, Chief, Investigational Drug Branch, CTEP, DCTD, NCI
  • Dr. Kristina Vouri, Burnham Institute for Medical Research
  • Dr. John Lazo, University of Pittsburg Drug Discovery Institute
  • Dr. W. Blaine Knight, Southern Research Institute
  • Dr. Lidia Sambucetti, SRI International
  • Dr. Milton Brown, Georgetown University
  • Dr. Gunda Georg, University of Minnesota
  • Dr. Donna Huryn, University of Pittsburgh
  • Dr. Gary Sulikowski, Vanderbilt Institute of Chemical Biology
  • Dr. Haian Fu, Emory University
  • Dr. James Wells, University of California, San Francisco
  • Dr. Stephen Frye, University of North Carolina
  • Dr. Chris Austin, NCGC, NIDR, NIH
For more information, visit http://dctd.cancer.gov/About/major_initiatives_NExt.htm
Debug: Show Debug
NLM Title: NCI Experimental Therapeutics Program, Chemical Biology Consortium / National Cancer Institute.
Author: National Cancer Institute (U.S.)
Publisher:
Abstract: (CIT): The purpose of this meeting is to announce and define the goals, process and procedures for the NCI"s Experimental Therapeutics (NExT) Program and of the newly created Chemical Biology Consortium (CBC). The Division of Cancer Treatment and Diagnosis (DCTD) and the Center for Cancer Research (CCR) are working in close collaboration to reinvigorate cancer drug development at NCI. Through a joint early therapeutics development program, extramural and intramural teams have prioritized a pipeline of NCI-driven targeted therapeutics for development. This program, called the NCI Experimental Therapeutics (NExT) program, combines the strengths of DCTD"s extensive expertise in anticancer drug development with CCR"s dynamic in-house research and its location within state-of-the-art facilities at the NIH Clinical Center. To further augment the discovery efforts of the NCI, DCTD is creating the Chemical Biology Consortium to enable the use and development of ultra-High Throughput Assays related to targets of interest for the purpose of developing hits that can then be optimized through iterative cycles of medicinal chemistry during the progression from in silico to in vitro to in vivo studies to define the anti-tumor activity of these new molecular entities.
Subjects: Antineoplastic Agents--pharmacology
Drug Design
Neoplasms--drug therapy
Therapies, Investigational
Publication Types: Congress
Webcasts
Download: To download this event, select one of the available bitrates:
[256k]  [384k]  [512k]    How to download a Videocast
NLM Classification: QZ 267
NLM ID: 101514416
CIT Live ID: 7779
Permanent link: https://videocast.nih.gov/launch.asp?15243